Long-term solid cancer risk among 5-year survivors of Hodgkin's lymphoma

被引:257
作者
Hodgson, David C.
Gilbert, Ethel S.
Dores, Grac A. M.
Schonfeld, Sara J.
Lynch, Charles F.
Storm, Hans
Hall, Per
Langmark, Froydis
Pukkala, Eero
Andersson, Michael
Kaijser, Magnus
Joensuu, Heikki
Foss, Sophie D.
Travis, Lois B.
机构
[1] Princess Margaret Hosp, Dept Radiat Oncol, Univ Hlth Network, Toronto, ON M5G 2M9, Canada
[2] Univ Toronto, Dept Radiat Oncol, Toronto, ON, Canada
[3] NCI, Div Canc Epidemiol & Genet, NIH, Dept Hlth & Human Serv, Bethesda, MD 20892 USA
[4] NCI, Div Canc Prevent, NIH, Dept Hlth & Human Serv, Bethesda, MD 20892 USA
[5] Univ Iowa, Iowa City, IA USA
[6] Danish Canc Soc, Copenhagen, Denmark
[7] Karolinska Inst, Stockholm, Sweden
[8] Norwegian Radium Hosp, Norwegian Canc Registry, Oslo, Norway
[9] Finnish Canc Registry, Inst Stat & Epidemiol Canc Res, FIN-00170 Helsinki, Finland
[10] Univ Helsinki, Cent Hosp, Helsinki, Finland
关键词
D O I
10.1200/JCO.2006.09.0936
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose Hodgkin's lymphoma (HL) survivors are known to be at substantially increased risk of solid cancers (SC). However, no investigation has used multivariate modeling to estimate the relative risk (RR), excess absolute risk (EAR), and cumulative incidence for specific attained ages and ages at HL diagnosis. Patients and Methods We identified 18,862 5-year HL survivors from 13 population-based cancer registries in North America and Europe. Poisson regression was used to evaluate the effects of age at diagnosis, attained age, latency, sex, treatment, and year of diagnosis on the RR and EAR of SC. Results Among 1,490 identified SC, 850 were estimated to be in excess. For most cancer sites, both RR and EAR decreased with age at HL diagnosis and showed strong dependencies on attained age. For a patient diagnosed at age 30 years and survived to >= 40 years, modeled risks were significantly elevated for cancers of the breast (RR = 6.1), other supradiaphragmatic sites (RR = 6.0), and infradiaphragmatic sites (RR = 3.7); the largest RR (20-fold) was observed for malignant mesothelioma. Thirty- year cumulative risks of SC for men and women diagnosed at 30 years were 18% and 26%, respectively, compared with 7% and 9%, respectively, in the general population. For young HL patients, risks of breast and colorectal cancers were elevated 10 to 25 years before the age when routine screening would be recommended in the general population. Conclusion Multivariable modeling demonstrates for the first time temporal changes in SC risk not evident in unadjusted analyses, and can facilitate the development of individualized risk assessment and the creation of screening strategies for early detection.
引用
收藏
页码:1489 / 1497
页数:9
相关论文
共 38 条
[1]   Long-term risk of second malignancy after treatment of Hodgkin's disease: the influence of treatment, age and follow-up time [J].
Abrahamsen, AF ;
Andersen, A ;
Nome, O ;
Jacobsen, AB ;
Holte, H ;
Abrahamsen, JF ;
Kvaloy, S .
ANNALS OF ONCOLOGY, 2002, 13 (11) :1786-1791
[2]   Long-term cause-specific mortality of patients treated for Hodgkin's disease [J].
Aleman, BMP ;
van den Belt-Dusebout, AW ;
Klokman, WJ ;
van't Veer, MB ;
Bartelink, H ;
van Leeuwen, FE .
JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (18) :3431-3439
[3]  
Anselmo AP, 2004, ANTICANCER RES, V24, P4045
[4]   MALIGNANT MESOTHELIOMA FOLLOWING RADIATION EXPOSURE [J].
ANTMAN, KH ;
CORSON, JM ;
LI, FP ;
GREENBERGER, J ;
SYTKOWSKI, A ;
HENSON, DE ;
WEINSTEIN, L .
JOURNAL OF CLINICAL ONCOLOGY, 1983, 1 (11) :695-700
[5]   Gastrointestinal cancer after treatment of Hodgkin's disease [J].
Birdwell, SH ;
Hancock, SL ;
Varghese, A ;
Cox, RS ;
Hoppe, RT .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1997, 37 (01) :67-73
[6]   ABVD plus subtotal nodal versus involved-field radiotherapy in early-stage Hodgkin's disease: Long-term results [J].
Bonadonna, G ;
Bonfante, V ;
Viviani, S ;
Di Russo, A ;
Villani, F ;
Valagussa, P .
JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) :2835-2841
[7]   EFFICACY AND TOXICITY OF VINBLASTINE, BLEOMYCIN, AND METHOTREXATE WITH INVOLVED-FIELD RADIOTHERAPY IN CLINICAL STAGE IA AND IIA HODGKINS-DISEASE - A BRITISH NATIONAL LYMPHOMA INVESTIGATION PILOT-STUDY [J].
BOTES, NP ;
WILLIAMS, MV ;
BESSELL, EM ;
HUDSON, GV ;
HUDSON, BV .
JOURNAL OF CLINICAL ONCOLOGY, 1994, 12 (02) :288-296
[8]  
BRESLOW NE, 1987, IARC SCI PUBL, V1
[9]  
Canadian Task Force on Preventive Health Care, 2001, CMAJ, V165, P206
[10]   Computed tomography screening for lung cancer in Hodgkin's lymphoma survivors: decision analysis and cost-effectiveness analysis [J].
Das, P ;
Ng, AK ;
Earle, CC ;
Mauch, PM ;
Kuntz, KM .
ANNALS OF ONCOLOGY, 2006, 17 (05) :785-793